Efficacy News and Research

RSS

More youngsters are using anti-obesity drugs

Thousands of children and adolescents are using anti-obesity drugs that in the UK are only licensed for use by adults. The number of young people receiving prescriptions for these drugs has increased 15-fold since 1999, but most stop using them before they could expect to see any benefit, according to a new study.

3 Sep 2009

MRG's new report on neurovascular embolectomy device market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.

3 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

$Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed$

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

This week TCA Cellular Therapy`s Medical Director Gabriel Lasala, M.D. presents advances in adult stem cell treatments for severe limb ischemia and refractory coronary ischemia at the European Society of Cardiology Congress in Barcelona, Spain.

2 Sep 2009

Positive results from second pivotal phase III trial for Lodotra

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

Lipose commences supply of Viafill Fat Transfer System

Lipose Corporation announced today that its Viafill™ Fat Transfer System is now available for sale to healthcare professionals. Viafill is an autologous fat transfer system that allows doctors to harvest fat from one part of the body and process it for use as injectable filler in another part of the body.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks.

2 Sep 2009

Altered gene network interaction plays an important role in brain tumors

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

1 Sep 2009

GS-101 effective in inhibiting and regressing corneal neovascularisation

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).

1 Sep 2009

Atrial fibrillation ablation - one of the fastest growing cardiology techniques

Atrial fibrillation ablation is one of the fastest growing techniques in cardiology and due to the very high number of patients that might be candidates to this procedure, a significant number of resources will have to be devoted to it to be able to treat them in the following years.

1 Sep 2009

H1N1 flu vaccine forms processing service launched by Quality Associates

Quality Associates, Inc. (QAI) www.qualityassociatesinc.com, an established provider of services and solutions for large-scale document management, imaging, and archiving, announced the launch of its H1N1 Flu Vaccine Forms Processing Service, a comprehensive approach to help states, cities, counties, and providers in the private sector successfully and accurately capture and record essential demographic and health data from medical consent forms – a critical step in the administration of the H1N1 vaccine to millions nationwide beginning this fall.

1 Sep 2009

Endosense raises USD 36 million in Series B financing

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009